Review
Rheumatology
Mehmet Soy, Gokhan Keser, Pamir Atagunduz, Melek Yalcin Mutlu, Alper Gunduz, Gizem Koybasi, Cemal Bes
Summary: The article discusses the importance of COVID-19 vaccination in AIIRD patients and provides precautions to be taken before vaccination, including vaccination when disease activity is under control and before the use of biological DMARDs.
CLINICAL RHEUMATOLOGY
(2021)
Article
Immunology
Sinem Nihal Esatoglu, Koray Tascilar, Hakan Babaoglu, Cemal Bes, Berna Yurttas, Servet Akar, Ozlem Pehlivan, Cansu Akleylek, Duygu Tecer, Emire Seyahi, Tuba Yuce-Inel, Nilufer Alpay-Kanitez, Erdal Bodakci, Emre Tekgoz, Seda Colak, Ertugrul Cagri Bolek, Suleyman Serdar Koca, Umut Kalyoncu, Ozan Cemal Icacan, Serdal Ugurlu, Hande Ece Oz, Vedat Hamuryudan, Gulen Hatemi
Summary: This study found that among patients with inflammatory rheumatic diseases (IRDs) and COVID-19, factors such as glucocorticoid use, chronic kidney disease, pulmonary disease, and obesity were associated with worse outcomes, while biologic disease-modifying antirheumatic drugs did not seem to be associated with worse outcomes.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Mohammad Shehab, Yasmin Zurba, Ali Al Abdulsalam, Ahmad Alfadhli, Sara Elouali
Summary: This study aimed to evaluate the prevalence of COVID-19 vaccination among patients receiving biologic therapies for inflammatory bowel disease (IBD). The results showed that the overall prevalence of vaccination was lower than that of the general population and World Health Organization (WHO) recommendation. Female patients, patients above the age of 50, and expatriates were more likely to receive the vaccine.
Article
Rheumatology
Rene Cordtz, Salome Kristensen, Rasmus Westermann, Kirsten Duch, Fiona Pearce, Jesper Lindhardsen, Christian Torp-Pedersen, Mikkel P. Andersen, Lene Dreyer
Summary: The study aimed to investigate the COVID-19 hospitalization incidence in unvaccinated and vaccinated patients with RA compared to controls. Results showed higher rates of COVID-19 hospitalization in both unvaccinated and vaccinated RA patients compared to controls, but a decrease in relative risk for RA patients after vaccination suggests a comparable benefit in most patients.
Article
Immunology
Martina Frodlund, Per Nived, Aikaterini Chatzidionysiou, Anna Sodergren, Eva Klingberg, Anders Bengtsson, Monika Hansson, Sophie Olsson, Elisa Pin, Lars Klareskog, Meliha C. Kapetanovic
Summary: This study aimed to investigate antibody responses in patients with inflammatory rheumatic diseases (IRD) treated with biologic/targeted disease modifying anti-rheumatic drugs (b/ts DMARDs) after the second and third dose of COVID-19 vaccine. The results showed that the percentage of patients with positive antibody response was significantly lower after two doses in patients receiving rituximab or abatacept treatment. However, the antibody response improved after the third dose.
Article
Virology
Qutaiba A. Al Khames Aga, Waseem H. Alkhaffaf, Tagreed H. Hatem, Kawthar F. Nassir, Yazan Batineh, Abdullah T. Dahham, Dimah Shaban, Luma A. Al Khames Aga, Manhal Y. R. Agha, Muaamar Traqchi
Summary: This study investigated the adverse effects associated with three different COVID-19 vaccines and found that local reactions were more common with Pfizer and AstraZeneca vaccines, while systemic events were more prevalent with AstraZeneca and Pfizer vaccines. There was no correlation between age or gender and the duration of adverse effects, and some participants reported unusual symptoms like swelling of eyelids and severe allergic reactions. Overall, Pfizer, AstraZeneca, and Sinopharm vaccines were deemed safe, with Sinopharm showing lower prevalence of adverse effects compared to the others.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Immunology
Martina Fabris, Ginevra De Marchi, Rossana Domenis, Federica Caponnetto, Silvia Guella, Chiara Dal Secco, Nicola Cabas, Salvatore De Vita, Antonio Paolo Beltrami, Francesco Curcio, Luca Quartuccio
Summary: This study evaluated the immune response to SARS-CoV-2 mRNA vaccination in patients with complex or rare systemic autoimmune diseases who were previously treated with or under continuous treatment with B-cell-targeted therapies. The results showed that even in the absence of circulating B cells, virus-specific cellular immunity can be induced, indicating that B-cell-targeted therapies do not preclude SARS-CoV-2 vaccination.
JOURNAL OF AUTOIMMUNITY
(2022)
Article
Multidisciplinary Sciences
Pol Campos-Mercade, Armando N. Meier, Florian H. Schneider, Stephan Meier, Devin Pope, Erik Wengstrom
Summary: Research suggests that modest monetary incentives can increase COVID-19 vaccination rates. Compared to behavioral nudges, monetary rewards have a more significant impact on boosting vaccination rates.
Article
Medicine, General & Internal
Yi-Wei Huang, Tsen-Fang Tsai
Summary: Flare-ups of psoriasis have been reported following COVID-19 vaccination, possibly due to the induction of Th17 cells. Psoriasis patients should be aware of potential fluctuations in disease activity after vaccination, but the benefits of vaccination in preventing severe COVID-19 infection and mortality outweigh the risks for those with psoriasis.
FRONTIERS IN MEDICINE
(2021)
Article
Multidisciplinary Sciences
Arindam Banerjee, Rudra Prosad Goswami, Moumita Chatterjee
Summary: This study evaluates the correlation of the size of the JAK/STAT network with treatment effect in rheumatoid arthritis, phenotype of viral infection, and effect of immunosuppressive agents on a system infected with coronavirus. The analysis shows a significant correlation between edges and minimum vertex cover with clinical efficacy, and these factors are also associated with the acuteness of viral infections. Baricitinib may be a promising target for the treatment of coronavirus infection.
SCIENTIFIC REPORTS
(2021)
Review
Virology
Aleksandra Anna Zasada, Aniela Darlinska, Aldona Wiatrzyk, Katarzyna Woznica, Kamila Forminska, Urszula Czajka, Malgorzata Glowka, Klaudia Lis, Paulina Gorska
Summary: The development of COVID-19 vaccines has been unprecedented in terms of speed, with various vaccine platforms receiving approval for human application.
Article
Dermatology
Zuleyha Ozgen, Hasan Aksoy, Ozlem Akin Cakici, Ayse Esra Koku Aksu, Ozan Erdem, Asude Kara Polat, Mehmet Salih Gurel
Summary: This study investigated the disease characteristics and demographic features of pemphigus patients during the COVID-19 pandemic, aiming to assess the impact of immunosuppressants on the course of COVID-19 in this patient group. The results showed that most patients had a non-serious disease, although a small number required hospitalization.
DERMATOLOGIC THERAPY
(2022)
Article
Immunology
Masaki Machida, Itaru Nakamura, Takako Kojima, Reiko Saito, Tomoki Nakaya, Tomoya Hanibuchi, Tomoko Takamiya, Yuko Odagiri, Noritoshi Fukushima, Hiroyuki Kikuchi, Shiho Amagasa, Hidehiro Watanabe, Shigeru Inoue
Summary: This study investigated the acceptance and hesitancy towards the COVID-19 vaccine in Japan, finding that 62.1% of participants were willing to get vaccinated. The research also revealed that vaccine acceptance was lower among women, adults aged 20-49 years, and those with a low-income level. Psychological factors, such as the perceived effectiveness of the vaccine and willingness to protect others, were identified as important factors associated with vaccine acceptance.
Article
Rheumatology
Jack Arnold, Shouvik Dass, Sarah Twigg, Colin H. Jones, Ben Rhodes, Peter Hewins, Mithun Chakravorty, Phil Courtney, Michael Ehrenstein, Md Yuzaiful Md Yusof, Edward M. Vital
Summary: Obinutuzumab appears to be effective and steroid-sparing in SLE patients with secondary non-response to rituximab.
Article
Rheumatology
Victoria Furer, Tali Eviatar, Devy Zisman, Hagit Peleg, Daphna Paran, David Levartovsky, Michael Zisapel, Ofir Elalouf, Ilana Kaufman, Roni Meidan, Adi Broyde, Ari Polachek, Jonathan Wollman, Ira Litinsky, Katya Meridor, Hila Nochomovitz, Adi Silberman, Dana Rosenberg, Joy Feld, Amir Haddad, Tal Gazzit, Muna Elias, Nizar Higazi, Fadi Kharouf, Gabi Shefer, Orly Sharon, Sara Pel, Sharon Nevo, Ori Elkayam
Summary: Vaccination with mRNA BNT162b2 vaccine showed reduced immunogenicity in patients with AIIRD compared to the general population, with risk factors including older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. However, most patients maintained stable disease activity post-vaccination.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Multidisciplinary Sciences
Benny Chain, Jack Arnold, Samia Akthar, Michael Brandt, David Davis, Mahdad Noursadeghi, Thabo Lapp, Changhua Ji, Surya Sankuratri, Yanjing Zhang, Lata Govada, Emmanuel Saridakis, Naomi Chayen
Meeting Abstract
Rheumatology
Jack E. Arnold, Edward M. J. Vital, Shouvik Dass, Aamir Aslam, Andy C. Rawstron, Sinisa Savic, Paul Emery, Yuzaiful Yusof
Meeting Abstract
Rheumatology
S. Pepple, J. Arnold, E. Vital, A. Rawstron, C. Pease, S. Dass, P. Emery, M. Y. Md Yusof
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Jack Arnold, Shouvik Dass, Sarah Twigg, Colin H. Jones, Ben Rhodes, Peter Hewins, Mithun Chakravorty, Phil Courtney, Michael Ehrenstein, Md Yuzaiful Md Yusof, Edward M. Vital
Summary: Obinutuzumab appears to be effective and steroid-sparing in SLE patients with secondary non-response to rituximab.
Article
Rheumatology
Md Yuzaiful Md Yusof, Jack Arnold, Benazir Saleem, Claire Vandevelde, Shouvik Dass, Sinisa Savic, Edward M. Vital, Paul Emery
Summary: This study aimed to assess the incidence of breakthrough SARS-CoV-2 infection and evaluate the predictors of moderate-to-severe COVID-19 outcomes in patients treated with rituximab. The study found that although the rate of SARS-CoV-2 breakthrough infection was high in vaccinated patients, the incidence of severe COVID-19 was similar to other severe infection events in this population.
LANCET RHEUMATOLOGY
(2023)
Article
Rheumatology
Sophanit Pepple, Jack Arnold, Edward M. Vital, Andrew C. Rawstron, Colin T. Pease, Shouvik Dass, Paul Emery, Md Yuzaiful Md Yusof
Summary: This study assessed the outcomes of rituximab treatment in primary Sjogren's syndrome and identified predictors of sustained clinical response. The results suggest that combining immunosuppressants with rituximab and aiming for complete B-cell depletion can increase the odds of response. The study highlights the importance of personalized treatment approaches in improving clinical outcomes in this condition.
ACR OPEN RHEUMATOLOGY
(2022)
